Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03301636
Title A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NewLink Genetics Corporation



Indoximod + Nivolumab

Indoximod + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST